The senior vice president of Technical Operations at Senti Biosciences discussed the company’s NK cell logic-gating platform and allogeneic approach.
Marty Giedlin, PhD
Advertisement
Articles by Marty Giedlin, PhD
Advertisement
Latest Updated Articles
Marty Giedlin, PhD, on Advantages of Allogeneic NK Cell Therapy ApproachesPublished: September 29th 2022 | Updated:
Advertisement
Advertisement
Trending on CGTlive®
1
Intellia Puts Phase 3 Trials for Transthyretin Amyloidosis Gene Editing Therapy Nex-Z on Hold Following Grade 4 Liver AE
2
M. Peter Marinkovich, MD, on Integrating Gene Therapy into Clinical Practice for Dermatologists
3
Quarter Century Update: The Continued Unknowns of Cell and Gene Therapy
4
